Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.51 -1.95 (-4.02%)
Official Closing Price Updated: 4:10 PM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill
Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735. 
Via Investor's Business Daily
3 Undervalued Healthcare Stocks You Can Buy Now and Hold Long-Term
The healthcare industry is one of the laggards of 2025. 
Via The Motley Fool
GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access
GoodRx stock rose 5.08% after it partnered with Novo Nordisk to offer Ozempic and Wegovy at a flat $499 monthly price for self-paying patients. 
Via Benzinga
Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4
A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors. 
Via MarketBeat
Topics Artificial Intelligence
Why Weight-Loss Drugmaker Novo Nordisk’s Stock Is Rising Premarket Today
Via Stocktwits
Autonomous Vehicles Hit an Inflection Point; GPT-5 Is Here
Motley Fool Money checks in on some stock market news. 
Via The Motley Fool
Topics Economy
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Stocks Muted Ahead Trump-Zelenskyy Meeting, First Solar Jumps: What's Moving Markets Monday?
Investor risk sentiment paused at the start of the week, as markets awaited details expected to emerge later when President Donald Trump meets with Ukrainian President Volodymyr Zelenskyy and European... 
Via Benzinga
Topics Government
Dayforce, Applied Digital, GoodRx, First Solar, TeraWulf: Stocks Making The Biggest Moves Today
Dayforce shares skyrocketed 26% in Monday’s midday trade after reports suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows
Novo Nordisk is showing signs that a comeback might be on the horizon after it hit the lows of its 52-week trading range. 
Via Benzinga
Ozempic And Wegovy Now Available Through GoodRx At Reduced Self-Pay Price, Stock Skyrockets
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S. 
Via Benzinga
Market Movers: UnitedHealth, Intel, and Novo Nordisk Among Top Performers Reshaping the Financial Landscape
The financial markets are abuzz with significant movements across various sectors, driven by a confluence of strategic investments, groundbreaking regulatory approvals, and the enduring influence of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Why Novo Nordisk Stock Popped Monday
Novo Nordisk stock looks so cheap, any good news at all can make it pop. 
Via The Motley Fool
Novo Nordisk Stock Surges After Pharma Major Cuts Ozempic Cost to $499 Per Month For Self-Paying Patients
The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost. 
Via Stocktwits
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug. 
Via Investor's Business Daily
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi &amp; Korsinsky to Learn More
Via TheNewswire.com
Topics Fraud Lawsuit
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
From Bernstein Liebhard LLP
Via GlobeNewswire
Dow Futures Decline After Recent Rally, All Eyes On Powell’s Jackson Hole Speech: NVO, UNH, FSLR, RUN, PANW Among Stocks To Watch
Via Stocktwits
Topics Stocks
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth. 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
1 Stock Down 40% This Year to Buy and Hold
This might be a wonderful entry point for long-term investors. 
Via The Motley Fool
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
The drugmaker's recent dip could also be a buying opportunity. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
Why Novo Nordisk Flew Almost 3% Higher on Friday
It seems to be holding off on price adjustments demanded by President Trump. 
Via The Motley Fool
Topics Government
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
Levi &amp; Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.